prostatitis
PROSTATITIS

Prostatitis is the inflammation of the prostate that may be caused by infection, chronic pelvic pain syndrome or asymptomatic prostate inflammation.

Prominent features are genitourinary, pelvic or rectal pain and lower urinary tract symptoms, eg urinary frequency, urgency, hesitancy, weak stream and straining on urination, dysuria, pain that increased with urination.

Introduction

  • A spectrum of disorders that affect men whose symptoms are referable to the lower urogenital tract & perineum

Etiology

  • Etiologic agents are the same for both acute bacterial prostatitis (ABP) & chronic bacterial prostatitis (CBP) & include E coli (most commonly isolated pathogen), Enterococcus sp, Klebsiella sp, Proteus sp, P aeruginosa, C trachomatis, U urealyticum, T vaginalis
    • Immune-deficient or human immunodeficiency virus (HIV) patients may have pathogens such as S typhi, M avium, M tuberculosis, Candida sp, C immitis, B dermatitidis, H capsulatum

Signs and Symptoms

  • Prominent features are genitourinary, pelvic or rectal pain & lower urinary tract symptoms, eg urinary frequency, urgency, hesitancy, weak stream & straining on urination, dysuria, pain that increased w/ urination
Editor's Recommendations
Most Read Articles
6 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
4 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.